Zentalis Pharmaceuticals (NASDAQ:ZNTL) Earns Neutral Rating from Wedbush
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Wedbush in a research note issued on Thursday,Benzinga reports. They presently have a $4.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 217.46% from the company’s current price. Other equities analysts also recently issued […]
Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Free Report)‘s stock had its “neutral” rating reaffirmed by analysts at Wedbush in a research note issued on Thursday,Benzinga reports. They presently have a $4.00 target price on the stock. Wedbush’s price objective suggests a potential upside of 217.46% from the company’s current price. Other equities analysts also recently issued […]
